Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Stopped Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib was very well tolerated, there was insufficient evidence of activity at the doses tested in the Phase 1b to advance to Phase 2.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoplasmacytoid Lymphoma
- Mantle-Cell Lymphoma
- Waldenstrom Macroglobulinemia
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
Interventions
Sponsor
Sunesis Pharmaceuticals